Noopept: Evidence, Mechanism, Dosing & Legal Status

Noopept (omberacetam, GVS-111; ethyl 1-(phenylacetyl)-L-prolylglycinate) is a synthetic, orally active proline-containing dipeptide ethyl ester designed in Russia as a peptide-derived nootropic.6 Its popularity as a "smart drug" is large; its proof in people is narrow. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Noopept is not an FDA-approved drug and is not a lawful U.S. dietary-supplement ingredient. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Noopept and how does it work?

Noopept is N-phenylacetyl-L-prolylglycine ethyl ester (molecular formula C17H22N2O4, molar mass roughly 318.4 g/mol), first synthesized in 1996 at the V.V. Zakusov Institute of Pharmacology.6 It is a dipeptide (proline-glycine) ethyl ester acylated with phenylacetic acid — a true peptide-derived small molecule rather than a long peptide, which is why it is orally bioavailable and crosses the blood-brain barrier.3 Structurally it is grouped with the racetam family and is reported to be active at doses roughly a thousand-fold lower than piracetam.6

The compound behaves as a prodrug of the endogenous neuropeptide cycloprolylglycine (cPG). Ester hydrolysis yields the free acid, with subsequent cyclization to cPG; because cPG is present in mammalian brain and has a longer residence than the rapidly cleared parent, it is considered a key contributor to the drug's prolonged effect.6 The mechanistic story — almost entirely preclinical — centers on three threads. First, neurotrophin upregulation: in rat hippocampus Noopept increased NGF and BDNF mRNA, with chronic 28-day dosing potentiating rather than diminishing the effect.4 Second, HIF-1 activation: in HEK293 cells Noopept selectively raised HIF-1 DNA-binding activity, with docking implicating inhibition of prolyl hydroxylase 2 and stabilization of HIF-1-alpha, upregulating cytoprotective and angiogenic genes.3 Third, glutamatergic and cholinergic modulation, with cPG described as a positive modulator of AMPA-receptor currents.3 The parent half-life is very short (about 16 minutes in rats), but human pharmacokinetics show slower, highly variable elimination and remained poorly characterized as of 2017.5

What is the evidence by indication?

The human evidence is confined to a narrow clinical population; everything else is preclinical or unproven. The table below summarizes the picture.

The cornerstone is Neznamov and Teleshova (2009), a 56-day comparative study in patients with mild cognitive disorders of vascular or post-traumatic organic brain disease, comparing Noopept 10 mg twice daily against piracetam 400 mg three times daily.1 Both groups improved on cognitive and mood measures, with the Noopept arm reportedly improving on standardized scales and showing a favorable effect on anxiety and affective symptoms.2 Supporting open-label experience in MCI and post-stroke patients is uncontrolled.5 The caveats are decisive: small, single-country literature; an active-comparator rather than rigorous placebo design; no independent Western replication; no meta-analysis; and a longest human trial of only about 56 days. That is why the cognitive indication is graded B, not A.

Neuroprotection sits a tier lower. In NGF-differentiated PC12 cells and alpha-synuclein neuroblastoma, Noopept pretreatment reduced amyloid-beta-induced apoptosis, lowered reactive oxygen species and tau Ser396 phosphorylation, and restored mitochondrial potential and neurite outgrowth.4 These are cell-culture findings with no qualifying human efficacy data in dementia. The dominant real-world use — boosting memory and focus in healthy people — has no supporting controlled human trials at all and relies on extrapolation from rodent data and the MCI literature.11 Readers can confirm the headline human trial directly on PubMed (PMID 19234797); no large, independent, placebo-controlled RCT and no meta-analysis exists for any indication.

What doses appear in the literature?

Reported strictly as information, not a protocol. The studied pharmaceutical regimen in the Russian cognitive-impairment literature was 10 mg orally twice daily — 20 mg per day — for courses of up to 56 days.1 Secondary and over-the-counter use cites a wider band of roughly 10 to 30 mg per day, but no dose has been validated as optimal and the longest human trial ran only about two months.6 Because the molecule is an orally bioavailable small molecule designed to cross the blood-brain barrier, the human clinical literature describes no injectable or reconstituted use — Noopept is not a reconstituted lyophilized peptide.3 A serious real-world caution applies to consumer products: independent testing found supplement units containing omberacetam at up to about 40.6 mg — roughly four times the 10 mg pharmaceutical dose — and frequently mislabeled, meaning the dose printed on a label cannot be trusted.7

How safe is Noopept?

Reported adverse events from clinical use and reviews include irritability, sleep disturbance or insomnia, increased blood pressure, headache (anecdotally choline-responsive), and gastrointestinal discomfort; in the comparator trial some treated patients reported sleep problems, irritability and raised blood pressure by study end.5 Preclinical toxicology reported low acute toxicity with no mutagenic, immunotoxic or allergenic signal at high chronic animal doses — but this does not establish human long-term safety.5 Theoretical, mechanism-based concerns include HIF-1/VEGF-mediated angiogenic signaling (undesirable in active malignancy or proliferative retinopathy) and a glutamatergic seizure-threshold consideration in susceptible individuals — neither demonstrated clinically.3 No formal human drug-interaction studies exist; precautionary concern attaches to other CNS stimulants and to antihypertensives. In practice the combination risk is amplified because contaminated supplements may co-contain phenibut, vinpocetine, picamilon and aniracetam — combinations never tested in humans.7 Precautionary contraindications include pregnancy and lactation, children and adolescents, uncontrolled hypertension, and significant hepatic or renal impairment.

What is the FDA and WADA status in 2026?

In the United States, Noopept (omberacetam) is not approved for any use and is not a lawful dietary-supplement ingredient.6 The FDA treats it as an unapproved new drug and piracetam analog requiring proper drug review and labeling, and it has been subject to import alerts; no 503A or 503B compounding pathway applies because it is not an approved drug and not on a recognized compounding bulk-substances list.6 Despite this, it persists in over-the-counter cognitive supplements, often mislabeled or combined with other unapproved drugs, as documented by Harvard's Cohen group.7 It is not a controlled or scheduled substance with the DEA. In Russia it is sold over-the-counter as a medicine; in the United Kingdom, production and import are not prohibited under the Psychoactive Substances Act, but sale or supply for human consumption is prohibited.6

For athletes the picture is interpretive rather than explicit. Noopept is not named on the in-force 2026 WADA Prohibited List.9 However, because it lacks current regulatory approval for human therapeutic use, it may fall within category S0 (non-approved substances), which is prohibited at all times. Status is therefore interpretive, and any tested athlete should verify the specific compound through GlobalDRO or their national anti-doping organization before use.10 Online vendors frequently label it "not for human consumption" to skirt drug law — a marker of an unregulated product, not a safety assurance.

Bottom line. Noopept is a mechanistically credible proline-glycine dipeptide nootropic and cycloprolylglycine prodrug whose mechanism far outruns its human evidence. What has actually been studied in people is narrow: small, mostly Russian trials in vascular or post-traumatic mild cognitive impairment, headlined by one 56-day active-comparator study (Grade B). Neuroprotection and neurotrophin claims are preclinical (Grade C), and the popular healthy-adult use is unproven. Layered on top is a serious product-integrity problem — unapproved, not a lawful supplement, import-alerted, yet sold OTC in frequently mislabeled or multi-drug-adulterated products. Regulatory facts here are current as of June 2026 and should be re-verified before relying on them.